MET and neoplasm: Yet, in keeping with concurrent de novo MET amplification as a mechanism of primary resistance to EGFR-TKIs, a retrospective Japanese study identified MET amplification at baseline in 11 of 35 EGFRm+ LAC patients treated with Gefitinib and showed that it predicted a higher risk of tumor progression and death [92].